Raftopoulos, R., Kuhle, J., Grant, D., Hickman, S. J., Altmann, D. R., Leppert, D., . . . Gnanapavan, S. (2021). Neurofilament results for the phase II neuroprotection study of phenytoin in optic neuritis. EUROPEAN JOURNAL OF NEUROLOGY, 28 (2), 587-594. doi:10.1111/ene.14591

Kapoor, R., Smith, K. E., Allegretta, M., Arnold, D. L., Carroll, W., Comabella, M., . . . Fox, R. J. (2020). Serum neurofilament light as a biomarker in progressive multiple sclerosis. NEUROLOGY, 95 (10), 436-444. doi:10.1212/WNL.0000000000010346

Cunniffe, N., Vuong, K. A., Ainslie, D., Baker, D., Beveridge, J., Bickley, S., . . . Coles, A. (2020). Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. doi:10.1136/jnnp-2020-324286

Goldman, M. D., LaRocca, N. G., Rudick, R. A., Hudson, L. D., Chin, P. S., Francis, G. S., . . . Cohen, J. A. (2019). Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data. NEUROLOGY, 93 (21), E1921-E1931. doi:10.1212/WNL.0000000000008519

Kapoor, R., Sellebjerg, F., Hartung, H. -. P., Arnold, D., Freedman, M. S., Jeffery, D., . . . Plavina, T. (2019). Natalizumab Reduces Serum Concentrations of Neurofilament Light Chain in Secondary Progressive Multiple Sclerosis Patients From the Phase 3 ASCEND Study. NEUROLOGY, 92 (15). LIPPINCOTT WILLIAMS & WILKINS.

Marta, M., Bianchi, L., Lieberman, D., Ciccarelli, O., Collorone, S., Kapoor, R., . . . Giovannoni, G. (2019). Oxcarbazepine as a neuroprotective agent in MS: a phase IIa trial (PROXIMUS). Presented at: 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS.

Lieberman, D. R., Giovannoni, G., Cafferty, F., Bianchi, L., Gnanapavan, S., Marta, M., . . . Kapoor, R. (2019). Seamless phase II-III adaptive trial design elements for progressive MS: Neurofilament light chain (phase II/interim endpoint), phase III endpoints and patient populations. Presented at: 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS.

Eshaghi, A., Young, A., Wijeratne, P., Prados, F., Kapoor, R., Chataway, J., . . . Ciccarelli, O. (2019). Subtyping and staging progressive MS using MRI. Presented at: 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS.

Kapoor, R., Ho, P. R., Campbell, N., Chang, I., Deykin, A., Forrestal, F., . . . Klodowska-Duda, G. (2018). Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. The Lancet Neurology, 17 (5), 405-415. doi:10.1016/S1474-4422(18)30069-3

Kapoor, R., Sellebjerg, F., Hartung, H. -. P., Arnold, D. L., Freedman, M. S., Jeffery, D., . . . Plavina, T. (2018). Natalizumab reduced serum levels of neurofilament light chain in secondary progressive multiple sclerosis patients from the phase 3 ASCEND study. MULTIPLE SCLEROSIS JOURNAL, 24, 988. SAGE PUBLICATIONS LTD.